MI-2 treatment led to increased cholesterol export and decreased cholesterol biosynthesis, leading to the depletion of intracellular cholesterol that ultimately reduces the viability of glioma cells in a manner independent of menin [397]. The gene discussed is MEN1; the disease is central nervous system cancer.